TP53 and leukemia: Intriguingly, prior cytotoxic treatment cannot directly induce genome-wide DNA damage or a leukemia-specific mutation but rather may facilitate the preferential expansion of a pre-leukemic clone harboring somatic TP53 mutations, which are resistant to chemotherapy.